ClinicalTrials.gg
CompletedNCT03771040Updated Dec 8, 2020

Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels

A Phase 3 interventional study of Masitinib and Placebo in Asthma, sponsored by AB Science. Completed at 5 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-12-08.

Sponsored by AB Science · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2020, 6 years 2 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2020.
  • Registered 2 years after the study started (first participant enrolled Dec 2016, registered Dec 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
347
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 147 studies in Asthma with a site in Argentina — 16 open to participants now, 25 under way, 12 of them phase 3. Asthma · Argentina.

Enrollment
92nd of 141
347 · median 517
Started
2016
with 7 others
Phase 3
82 of 147
7 open now
Registered
93rd of 147
by date

Among the 147 studies in Asthma with a site in Argentina, this one is the 92nd largest by enrollment of the 141 interventional ones that give a count, is one of 8 that started in 2016, is one of 82 in phase 3, and was the 93rd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

16 of the 147 studies in Asthma with a site in Argentina are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Asthma with a site in Argentina, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of masitinib (6 mg/kg/day) in severe persistent asthma, uncontrolled with high dose of inhaled corticosteroid and with elevated eosinophil levels.

Read the detailed description

Masitinib is a selective tyrosine kinase inhibitor. It is known that activation of inflammatory cells, such as mast cells, and fibrous tissue remodeling are associated with c-Kit, Lyn and PDGFR kinase signaling pathways; all key targets of masitinib. This is a multicenter, double-blind, randomized, parallel-group (ascending dose titration of masitinib to 6.0 mg/kg/day and matching placebo), comparative study of oral masitinib in the treatment of patients with severe asthma, uncontrolled with high dose of inhaled corticosteroid and with elevated eosinophil levels. Eligible patients will be treated during at least 48 weeks.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Severe persistent asthma
  • Eosinophil
  • Tyrosine kinase inhibitor
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria include:

  • Patients with a physician diagnosis of persistent asthma for at least 12 months based on Global Initiative for Asthma (GINA) 2009 Guidelines whose asthma is partially controlled or uncontrolled on inhaled (ICS) / long-acting beta2-agonists (LABA) combination therapy.
  • Patient with elevated eosinophil level related to asthma at baseline: ≥0.15 K/uL or patient with eosinophil level ≥0.15 K/uL related to asthma demonstrated in the year prior to screening
  • Non-smoker patient for at least one year and with a prior tobacco consumption \<10 packs/year

Main exclusion criteria include:

  • Female patient who is pregnant or lactating
  • Asthmatic patient still exposed to allergens or to triggering factors influencing asthma control
  • and/or other lung diseases impairing Pulmonary Function Tests
  • Within 12 weeks prior to screening, patient who received oral corticosteroids for any other reason than to treat severe asthma exacerbation (patients needing long term corticosteroids intake to control basal asthma condition)
  • Patient with history of acute infectious sinusitis or respiratory tract infection within 4 weeks prior to screening visit
  • Patient with active lung disease other than asthma (e.g. chronic bronchitis)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
347 participants (actual)

Study arms

  • Experimental
    Masitinib (titration to 6.0 mg/kg/day)

    Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control.

    Drug: Masitinib

  • Placebo comparator
    Placebo

    Participants receive matched placebo

    Drug: Placebo

Interventions

  • Also known as: AB1010

  • DrugPlacebo

    Also known as: Placebo Oral Tablet

06

What researchers measure

Primary outcomes

  1. Severe asthma exacerbation rate

    The number of severe asthma exacerbations over time frame of outcome measure

    Time frame: Duration of patient treatment exposure, assessed until withdrawal from study, study completion date, or for a maximum of 60 months

Secondary outcomes

  1. Asthma exacerbation rate

    The number of asthma exacerbations over time frame of outcome measure

    Time frame: Duration of patient treatment exposure, assessed until withdrawal from study, study completion date, or for a maximum of 60 months

  2. Asthma Control Questionnaire (ACQ)

    Asthma Control Questionnaire (ACQ) * Type of questionnaire-description: A simple questionnaire to measure the adequacy of asthma control and change in asthma control which occurs either spontaneously or as a result of treatment. * Number of items: 7 items; 1 week recall (for items on symptoms and rescue inhaler use) * Number of domains \& categories: ACQ has a multidimensional construct assessing symptoms (5 items--self-administred) and rescue inbronchodilator use (1 item-self-administered), and FEV1% (1 item) completed by clinic staff * Scaling of items: 7-point scale (0=no impairment, 6= maximum impairment for symptoms and rescue use; and 7 categories for FEV1%). Scores range between 0 (totally controlled) and 6 (severely uncontrolled).

    Time frame: 48 weeks

07

Study locations

5 sites
  • Centro Respiratorio Quilmes
    Buenos Aires, Argentina
  • Sarawak General Hospital
    Kuching, 93586, Malaysia
  • Clínica Universidad de los Andes
    Miraflores, Peru
  • The Philippine Heart Center
    Quezon City, Philippines
  • National institute of phthisiology and pulmonology named after F.G. Yanovsky NAMS of Ukraine
    Kiev, 03680, Ukraine
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Sep 2020, 45 months.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 45 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2018
First posted
Dec 10, 2018
StartActual
Dec 2016
Primary completionActual
Sep 2020
CompletionActual
Sep 2020
Results delay requested
Dec 7, 2020
Last update
Dec 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03771040
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Dec 10, 2018
Start date
Dec 2016
Primary completion
Sep 2020
Completion
Sep 2020
Last update
Dec 8, 2020

Study contacts

Lavinia Davidescu, MD, PhD
principal investigator · University of Medicine and Pharmacy Oradea, Oradea, Romania.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion